Physician profile
Aundria G Lear
NPI 1528376860
$1,694.86
in general payments reported to CMS, 2019-2025
12 companies · $516 in 2025
The $516 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $44.77 · 2021: $247 · 2022: $174 · 2023: $263 · 2024: $347 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Entertainment: $92.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.54 |
| Entertainment | $92.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $433.05 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $366.73 | 2021-2025 | Precision 1, Precision7, Total30 |
| Bausch & Lomb Americas INC. | $153.34 | 2022-2024 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.59 | 2019-2021 | |
| Lkc Technologies, INC. | $126.55 | 2023-2025 | |
| Kala Pharmaceuticals, INC. | $124.99 | 2021 | |
| Topcon Healthcare, INC. | $107.12 | 2024 | |
| Optos, INC. | $92.72 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $62.81 | 2023-2024 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $40.07 | 2022-2025 | |
| Glaukos Corporation | $27.69 | 2025 | Photrexa Viscous and Photrexa |
| Carl Zeiss Meditec Ag | $17.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aundria Lear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.